Steers, M.D., and Pierre A.

Viagra Connect is an over-the-counter treatment for erectile dysfunction.
It contains sildenafil, which improves blood flow to the penis.
Available in pharmacies without a prescription.
Patients should consult a pharmacist before use.
Suitable for men aged 18 and over.
Must be taken at least 30 minutes before activity.

Wicker, M.D. Oral Sildenafil in the Treatment of Erectile Dysfunction – James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson (2007).

Viagra Connect requires a brief health assessment at purchase.
Patients should disclose any health issues or medications.
Alcohol consumption may reduce effectiveness.
It does not cause an instant erection; arousal needed.
Side effects are usually mild and temporary.
Seek medical advice if experiencing persistent problems.

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction – Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction – reuters.com – Erectile dysfunction drugs vary in effectiveness, side effects – While we've ensured that everything you read on the Health Centre is medically reviewed and approved, information presented here is not intended to be a substitute for professional medical advice, diagnosis, or treatment. It should never be relied upon for specific medical advice. If you have any questions or concerns, please talk to your doctor. Back to Journals » Patient Preference and Adherence » Volume 18 Authors Li JZ , Lem JA, Younus M, Donde SS, Collins J, Zou KH Editor who approved publication: Dr Johnny Chen Jim Z Li,1 Joanna Asia Lem,2 Muhammad Younus,2 Shaantanu S Donde,3 Janine Collins,4 Kelly H Zou1 1Global Medical Analytics, Real-World Evidence, and Health Economics & Outcomes Research Viatris Inc., Canonsburg, PA, USA; 2Safety Surveillance Research, Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA; 3Medical Affairs - Developed Markets, Viatris Inc., Dorking, UK; 4Safety, Epidemiology, Registries and Risk Management Department, UBC, Geneve, SwitzerlandCorrespondence: Kelly H Zou, Global Medical Analytics, Real-World Evidence, and Health Economics & Outcomes Research, Viatris Inc., Canonsburg, PA, USA, Tel +1.212-722-0087, Email [email protected]Purpose: A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription Viagra Connect® (VC) to erectile dysfunction (ED) patients in United Kingdom (UK). A survey aimed to evaluate the effectiveness of aRMMs.Methods: A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. Descriptive statistics were used.Results: The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%).

What is Viagra?

Furthermore, 85.5% of patients were advised on how to take VC correctly, 82.2% on possible side effects for which they might have to discontinue taking VC and consult their doctor, 80.1% on being informed that ED could be caused by underlying conditions. About 65.0% reported that they had visited (19.2%) or planned to visit (45.8%) their doctor. A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.Conclusion: This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.Plain Language Summary: A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK).A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists.The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED. Additionally, most of the patients had consulted or planned to consult their doctors, on how to take VC correctly, on possible side effects for which they might have to discontinue taking VC and consult their doctor, on being informed that ED could be caused by underlying conditions, and on lifestyle modifications.

Pharmacists’ Advice to Patients to Consult Their Doctor Within 6 Months of First Supply

A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.Keywords: aRMM, erectile dysfunction, pharmacist, sildenafil citrate Erectile dysfunction (ED) is the inability to achieve or maintain an erection that is sufficient for satisfactory sexual performance.1 The overall prevalence of self-reported ED in men across aged 40–70 years has been estimated to be 45.2%.2 Organic (ie, neurogenic, endocrinological, vasculogenic, or drug-induced), psychogenic, or mixed causes may attribute to ED.3,4 ED may be a presenting symptom of undetected or underlying cardiovascular disease (CVD) in men.5 ED and CVD share several risk factors including advanced age, tobacco use, excessive alcohol consumption, diabetes mellitus, hyperlipidemia, obesity, depression among others.6,7 Additionally, ED is also known to cause substantial negative effects on the patient’s self-esteem, quality of life and emotional status.8,9 There are several treatment options recommended by European guidelines for ED management including intracavernosal injection, vacuum device, oral therapy with phosphodiesterase type 5 (PDE-5) inhibitors, topical/intra-urethral alprostadil along with lifestyle modification and patient education. Amongst all the treatment options, pharmacological treatment with oral PDE-5 inhibitors remain the main stay of treatment of ED.10 Sildenafil citrate is a potent and selective inhibitor of cyclic- guanosine monophosphate-specific phosphodiesterase enzyme which causes relaxation of smooth muscle in the corpus cavernosum.11 Eventually, sildenafil restores the natural erectile response to sexual stimulation and has been effectively used in the treatment of patient population with ED of varying etiologies and with diverse comorbidities.3,4,12 Sildenafil citrate (Viagra®), supplied via prescription, was approved in the European Union (EU) in 1998 for treatment of ED. A Decentralized Procedure (DCP) application for non-prescription (ie, behind the counter) 50 mg sildenafil (marketed as Viagra Connect® [VC] 50 mg film-coated tablets) was approved in the UK in November 2017 and became available in pharmacies in the UK in April 2018.13 This launch of VC in the UK, and its availability as a “behind the counter” (pharmacist-supervised) medicine augments the availability of pharmacists to help men to deal with both the physical and emotional impact of ED, and other wider potential health concerns associated with ED. To facilitate this, before and after generic viagra professional sildenafil 100mg launch of behind the counter VC, a pharmacist education program of additional risk minimization measures (aRMM, as defined by EMA [European Medicines Agency]), comprising a training guide and a checklist regarding the safe use of VC was implemented. Using online resources, printed materials and in-store face-to-face sessions, pharmacists were trained to assess ED patients’ suitability of VC including an assessment of comorbidities and concomitant medications and to advise ED patients to consult their doctors within 6 months in order to assess any underlying health issues and the risk of misdiagnosis. Furthermore, 85.5% of patients were advised on how to take VC correctly, 82.2% on possible side effects for which they might have to discontinue taking VC and consult their doctor, 80.1% on being informed that ED could be caused by underlying conditions. About 65.0% reported that they had visited (19.2%) or planned to visit (45.8%) their doctor.

Important to check for allergies to sildenafil before use.
Side effects like dizziness should be taken seriously.
Consult a doctor if you experience vision changes.
Viagra Connect does not protect against STDs.
It’s recommended to avoid caffeine before taking.
Medication should be used responsibly and as directed.

A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.Conclusion: This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.Plain Language Summary: A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK).A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire.

Product	Dosage	Quantity + Bonus	Price
Viagra Soft Tabs	100mg	180 + 10 Pills	314.95€ 299.95€
Viagra Super Active	100mg	30 + 6 Pills	64.09€ 61.04€
Viagra Super Active	100mg	270 + 30 Pills	390.61€ 372.01€
Viagra Professional	100mg	180 + 4 Pills	337.30€ 321.24€
Viagra Generic	50mg	360 + 10 Pills	225.33€ 214.60€
Viagra Soft Tabs	100mg	10 Pills	36.93€ 35.17€
Viagra Professional	100mg	360 + 6 Pills	527.09€ 501.99€
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€
Viagra Oral Jelly	100mg	90 + 8 Sachets	258.02€ 245.73€
Viagra Super Active	100mg	180 + 20 Pills	280.97€ 267.59€
Viagra Generic	25mg	270 + 8 Pills	184.26€ 175.49€
Viagra Generic	200mg	270 + 10 Pills	379.76€ 361.68€
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€
Viagra Oral Jelly	100mg	21 Sachets	78.66€ 74.91€
Viagra Original	100mg	34 + 2 Pills	163.67€ 155.88€

Patients were assessed for the suitability of VC and received appropriate advice from pharmacists.The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED.

Priligy (Dapoxetine) 60mg - 6 Tablets

This exploratory patient survey was conducted as part of the aRMM evaluation to assess patients’ experience while purchasing VC in a pharmacy without a prescription. This was achieved by knowing whether patients reported that they were assessed by a pharmacist for their suitability to receive VC and if they were advised by pharmacist to consult their doctor within 6 months of first supply. The survey also ascertained if patients reported having visited their doctor or planned to visit their doctor in the near future, being advised about the safe use of VC, potential causes of ED and lifestyle modifications by their pharmacist. This was a cross-sectional, web-based survey conducted in the UK between October 2020 and June 2021. A pre-testing of survey questions was conducted in a sample of 29 patients prior to the implementation of the survey.

Patient and Pharmacy Characteristics

This user-testing assessed the clarity of survey questions for interest and acceptance of the polls amongst the participants, as well as the flow and ease of completing the surveys. The findings and recommendations from the survey pre-testing were incorporated into the final version and tested in two pilot surveys for further refinement.8,14 This patient survey was administered online anonymously and expected to take approximately 5 minutes to complete by the participants. The survey was conducted in select Boots pharmacy stores, independent pharmacy stores and regional multiple pharmacies. Pharmacies were invited to participate in the study based on their monthly VC sales data during the months of March, April, and May 2020. Also, Pharmacies throughout the UK selected, to maximize patient representativeness. Additionally, most of the patients had consulted or planned to consult their doctors, on how to take VC correctly, on possible side effects for which they might have to discontinue taking VC and consult their doctor, on being informed that ED could be caused by underlying conditions, and on lifestyle modifications. A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.Keywords: aRMM, erectile dysfunction, pharmacist, sildenafil citrate Erectile dysfunction (ED) is the inability to achieve or maintain an erection that is sufficient for satisfactory sexual performance.1 The overall prevalence of self-reported ED in men across aged 40–70 years has been estimated to be 45.2%.2 Organic (ie, neurogenic, endocrinological, vasculogenic, or drug-induced), psychogenic, or mixed causes may attribute to ED.3,4 ED may be a presenting symptom of undetected or underlying cardiovascular disease (CVD) in men.5 ED and CVD share several risk factors including advanced age, tobacco use, excessive alcohol consumption, diabetes mellitus, hyperlipidemia, obesity, depression among others.6,7 Additionally, ED is also known to cause substantial negative effects on the patient’s self-esteem, quality of life and emotional status.8,9 There are several treatment options recommended by European guidelines for ED management including intracavernosal injection, vacuum device, oral therapy with phosphodiesterase type 5 (PDE-5) inhibitors, topical/intra-urethral alprostadil along with lifestyle modification and patient education. Amongst all the treatment options, pharmacological treatment with oral PDE-5 inhibitors remain the main stay of treatment of ED.10 Sildenafil citrate is a potent and selective inhibitor of cyclic- guanosine monophosphate-specific phosphodiesterase enzyme which causes relaxation of smooth muscle in the corpus cavernosum.11 Eventually, sildenafil restores the natural erectile response to sexual stimulation and has been effectively used in the treatment of patient population with ED of varying etiologies and with diverse comorbidities.3,4,12 Sildenafil citrate (Viagra®), supplied via prescription, was approved in the European Union (EU) in 1998 for treatment of ED.

VIAGRA Connect 50mg - 4 Tablets

Steers, M.D., and Pierre A. Wicker, M.D. Oral Sildenafil in the Treatment of Erectile Dysfunction – James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson (2007). Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction – Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction – reuters.com – Erectile dysfunction drugs vary in effectiveness, side effects – While we've ensured that everything you read on the Health Centre is medically reviewed and approved, information presented here is not intended to be a substitute for professional medical advice, diagnosis, or treatment. It should never be relied upon for specific medical advice.

Patients’ Experience Regarding the Advice from the Pharmacist to Consult Their Doctor Within 6 Months of First Supply of VC

If you have any questions or concerns, please talk to your doctor. Back to Journals » Patient Preference and Adherence » Volume 18 Authors Li JZ , Lem JA, Younus M, Donde SS, Collins J, Zou KH Editor who approved publication: Dr Johnny Chen Jim Z Li,1 Joanna Asia Lem,2 Muhammad Younus,2 Shaantanu S Donde,3 Janine Collins,4 Kelly H Zou1 1Global Medical Analytics, Real-World Evidence, and Health Economics & Outcomes Research Viatris Inc., Canonsburg, PA, USA; 2Safety Surveillance Research, Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA; 3Medical Affairs - Developed Markets, Viatris Inc., Dorking, UK; 4Safety, Epidemiology, Registries and Risk Management Department, UBC, Geneve, SwitzerlandCorrespondence: Kelly H Zou, Global Medical Analytics, Real-World Evidence, and Health Economics & Outcomes Research, Viatris Inc., Canonsburg, PA, USA, Tel +1.212-722-0087, Email [email protected]Purpose: A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription Viagra Connect® (VC) to erectile dysfunction (ED) patients in United Kingdom (UK). A survey aimed to evaluate the effectiveness of aRMMs.Methods: A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. Descriptive statistics were used.Results: The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%). A Decentralized Procedure (DCP) application for non-prescription (ie, behind the counter) 50 mg sildenafil (marketed as Viagra Connect® [VC] 50 mg film-coated tablets) was approved in the UK in November 2017 and became available in pharmacies in the UK in April 2018.13 This launch of VC in the UK, and its availability as a “behind the counter” (pharmacist-supervised) medicine augments the availability of pharmacists to help men to deal with both the physical and emotional impact of ED, and other wider potential health concerns associated with ED.

What are Sildenafil 50mg Tablets?

To facilitate this, before and after generic viagra professional sildenafil 100mg launch of behind the counter VC, a pharmacist education program of additional risk minimization measures (aRMM, as defined by EMA [European Medicines Agency]), comprising a training guide and a checklist regarding the safe use of VC was implemented. Using online resources, printed materials and in-store face-to-face sessions, pharmacists were trained to assess ED patients’ suitability of VC including an assessment of comorbidities and concomitant medications and to advise ED patients to consult their doctors within 6 months in order to assess any underlying health issues and the risk of misdiagnosis.

Aspect	Description	Regulation/Standard
Data Encryption	All personal data encrypted during transmission	GDPR, HIPAA (if applicable)
Data Storage	Secure storage with restricted access	Data protection laws
User Consent	Users must agree to terms before submitting form	Legal requirement
Privacy Policy	Outlines data usage and user rights	Available on the website

This exploratory patient survey was conducted as part of the aRMM evaluation to assess patients’ experience while purchasing VC in a pharmacy without a prescription.

How to use Hycosan Extra Dry Eye Drops

This was achieved by knowing whether patients reported that they were assessed by a pharmacist for their suitability to receive VC and if they were advised by pharmacist to consult their doctor within 6 months of first supply. The survey also ascertained if patients reported having visited their doctor or planned to visit their doctor in the near future, being advised about the safe use of VC, potential causes of ED and lifestyle modifications by their pharmacist. This was a cross-sectional, web-based survey conducted in the UK between October 2020 and June 2021. A pre-testing of survey questions was conducted in a sample of 29 patients prior to the implementation of the survey. This user-testing assessed the clarity of survey questions for interest and acceptance of the polls amongst the participants, as well as the flow and ease of completing the surveys. The findings and recommendations from the survey pre-testing were incorporated into the final version and tested in two pilot surveys for further refinement.8,14 This patient survey was administered online anonymously and expected to take approximately 5 minutes to complete by the participants. The survey was conducted in select Boots pharmacy stores, independent pharmacy stores and regional multiple pharmacies. Pharmacies were invited to participate in the study based on their monthly VC sales data during the months of March, April, and May 2020. Also, Pharmacies throughout the UK selected, to maximize patient representativeness. All those patients who purchased VC from the participating pharmacies, received an invitation to partake in the survey. Pharmacists distributed survey invitation leaflets to all the patients during the survey period, according to a standard script. The recruitment of patients was carried out by the pharmacist at the point of supply of VC. The invitation leaflet had details regarding website address, introduction, and purpose of the survey, how and to whom the data would be reported, and the measures taken to preserve their confidentiality.

Medication details

All those patients who purchased VC from the participating pharmacies, received an invitation to partake in the survey. Pharmacists distributed survey invitation leaflets to all the patients during the survey period, according to a standard script. The recruitment of patients was carried out by the pharmacist at the point of supply of VC. The invitation leaflet had details regarding website address, introduction, and purpose of the survey, how and to whom the data would be reported, and the measures taken to preserve their confidentiality. To begin with, screening questions were asked to determine if patients were eligible to participate in the study and those who met the inclusion criteria were allowed to complete the full survey.

Statistical analysis

To begin with, screening questions were asked to determine if patients were eligible to participate in the study and those who met the inclusion criteria were allowed to complete the full survey.